Cover Image
市場調查報告書

非小細胞肺癌治療藥的全球市場:2015年∼2019年

Global Non-Small Cell Lung Cancer Therapeutics Market 2015-2019

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 312477
出版日期 內容資訊 英文 78 Pages
訂單完成後即時交付
價格
Back to Top
非小細胞肺癌治療藥的全球市場:2015年∼2019年 Global Non-Small Cell Lung Cancer Therapeutics Market 2015-2019
出版日期: 2015年10月21日 內容資訊: 英文 78 Pages
簡介

全球非小細胞肺癌治療藥市場,預計2014年∼2019年以6.77%的年複合成長率成長。

本報告提供全球非小細胞肺癌治療藥市場相關調查分析、市場規模與成長率、市場趨勢、市場的推動要素與課題、市場機會驗證、主要供應商等相關的系統性資訊。

第1章 摘要整理

  • 焦點

第2章 調查範圍

  • 市場概要
  • 主要供應商產品

第3章 市場調查手法

  • 調查手法
  • 經濟指標

第4章 產品簡介

第5章 簡介

  • 主要市場焦點

第6章 疾病概要

  • 關於疾病
  • 危險因素
  • 徵兆與症狀
  • 診斷
  • 分期
  • 治療
  • 流行病學

第7章 產品研發線

  • 開發平台候補相關資訊

第8章 市場形勢

  • 市場概要
  • 市場規模與預測
  • 波特的五力分析

第9章 市場區隔:各分子類型

  • 生技藥品
  • 小分子

第10章 市場區隔:各給藥途徑

  • 口服
  • 非口服

第11章 地理區分

第12章 推動市場要素

第13章 推動因素的影響

第14章 市場課題

第15章 推動因素與課題的影響

第16章 市場趨勢

第17章 業者情勢

  • 競爭模式
  • 市場分析
  • 其他卓越供應商

第18章 主要供應商分析

  • AstraZeneca
  • Celgene
  • Eli Lilly
  • F. Hoffmann-La Roche
  • Pfizer

第19章 附錄

第20章 關於Technavio

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: IRTNTR7475

About non-small cell lung cancer therapeutics

Non-small cell lung cancer occurs when normal cells grow and multiply without control after undergoing a cell transformation. Lung cancer is the leading cause of cancer deaths worldwide, and the incidence of lung cancer is increasing significantly. Lung cancer is the common cause of mortality and morbidity not only in developed countries but also in developing countries. One of the most common types of lung cancer is non-small cell lung cancer. It grows and spreads quite slowly. Smoking is considered as a major cause of lung cancer, although lung cancer also occurs in non-smokers. There are three main types of non-small cell lung cancer: squamous cell (epidermoid) carcinoma, adenocarcinoma, and large cell (undifferentiated) carcinoma. Some of the common symptoms associated with non-small cell lung cancer are chest pain, a cough that does not go away, coughing up blood, fatigue, loss of appetite, losing weight without trying, shortness of breath, and wheezing.

Technavio's analysts forecast the global non-small cell lung cancer therapeutics market to grow at a CAGR of 6.77% over the period 2014-2019.

Covered in this report

The report covers the current scenario and the growth prospects of the global non-small cell lung cancer therapeutics market for the period of 2015-2019. To calculate the market size, the report considers revenue generated through the sales of various drugs used for the treatment of non-small cell lung cancer.

Technavio's report, Global Non-Small Cell Lung Cancer Therapeutics Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, APAC, and Europe; it also covers the landscape of the global non-small cell lung cancer therapeutics market and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

Key regions

  • Americas
  • APAC
  • Europe

Key vendors

  • AstraZeneca
  • Celgene
  • Eli Lilly
  • F. Hoffmann-La Roche
  • Pfizer

Other Prominent Vendors

  • Abbvie
  • Aetna
  • Agennix
  • Amgen
  • BetaPharma
  • Bionumerik Pharmaceuticals
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • CBT Pharma
  • Celldex Therapeutics
  • Dainippon Pharma
  • Eisai Pharmaceuticals
  • GlaxoSmithKline
  • Helsinn
  • IMClone Systems
  • IsisPharma
  • Kadmon
  • Kyowa Hakko Kirin
  • MabVax Therapeutics
  • Merck
  • Novartis
  • OncoGenex
  • OSI Pharmaceuticals
  • Peregrine
  • Pierre Fabre
  • Qiagen
  • Sanofi
  • Synta Pharmaceuticals
  • Teva Pharmaceuticals

Key market driver

  • Promising drug pipeline
  • For a full, detailed list, view our report

Key market challenge

  • High cost of therapy
  • For a full, detailed list, view our report

Key market trend

  • Personalized medicine
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

Table of Contents

PART 01: Executive summary

  • Highlights

PART 02: Scope of the report

Market overview

  • Top vendor offerings

PART 03: Market research methodology

  • Research methodology
  • Economic indicators

PART 04: Product profiles

PART 05: Introduction

Key market highlights

PART 06: Disease overview

  • Understanding the disease
  • Risk factors
  • Signs and symptoms
  • Diagnosis
  • Staging
  • Treatment
  • Epidemiology

PART 07: Pipeline portfolio

  • Information on pipeline candidates

PART 08: Market landscape

Market overview

  • Market size and forecast
  • Five forces analysis

PART 09: Market segmentation by molecule type

  • Biologics
  • Small molecules

PART 10: Market segmentation by route of administration

  • Oral
  • Parenteral

PART 11: Geographical segmentation

PART 12: Market drivers

PART 13: Impact of drivers

PART 14: Market challenges

PART 15: Impact of drivers and challenges

PART 16: Market trends

PART 17: Vendor landscape

  • Competitive scenario
  • Market analysis 2014
  • Other prominent vendors

PART 18: Key vendor analysis

  • AstraZeneca
  • Celgene
  • Eli Lilly
  • F. Hoffmann-La Roche
  • Pfizer

PART 19: Appendix

  • List of abbreviations

PART 20: Explore Technavio

List of Exhibits

  • Exhibit 01: Product offerings
  • Exhibit 02: Types of non-small cell lung cancer
  • Exhibit 03: Gene mutations in non-small cell lung cancer
  • Exhibit 04: Risk factors for non-small cell lung cancer
  • Exhibit 05: Signs and symptoms of non-small cell lung cancer
  • Exhibit 06: Tests for diagnosis of non-small cell lung cancer
  • Exhibit 07: Staging of non-small cell lung cancer
  • Exhibit 08: Management of non-small cell lung cancer
  • Exhibit 09: Types of radiation therapy for non-small cell lung cancer
  • Exhibit 10: Photodynamic therapy uses light to actuate a drug in the body, which kills abnormal cells.Non-small cell lung cancer treatment algorithm
  • Exhibit 11: Phase III pipeline molecules for non-small cell lung cancer
  • Exhibit 12: Global non-small cell lung cancer therapeutics market 2014-2019 ($ billions)
  • Exhibit 13: Five forces analysis
  • Exhibit 14: Global non-small cell lung cancer therapeutics market segmentation by molecule type
  • Exhibit 15: Global non-small cell lung cancer therapeutics market segmentation by route of administration
  • Exhibit 16: Global non-small cell lung cancer market by geographical segmentation 2014
  • Exhibit 17: Impact of drivers
  • Exhibit 18: Impact of drivers and challenges
  • Exhibit 19: F. Hoffmann-La Roche: Global YoY growth and revenue of Avastin 2011-2014 ($ millions)
  • Exhibit 20: F. Hoffmann-La Roche: Key takeaways
  • Exhibit 21: Alimta: Global YoY growth and revenue 2011-2014 ($ millions)
  • Exhibit 22: Gemzar: Global YoY growth and revenue 2008-2011 ($ millions)
  • Exhibit 23: Eli Lilly: Key takeaways
  • Exhibit 24: Abraxane: Global YoY growth and revenue 2011-2014 ($ millions)
  • Exhibit 25: Celgene: Key takeaways
  • Exhibit 26: Iressa: Global YoY growth and revenue 2011-2014 ($ millions)
  • Exhibit 27: Iressa: YoY growth and revenue in Western Europe 2011-2014 ($ millions)
  • Exhibit 28: Iressa: YoY growth and revenue in established ROW 2011-2014 ($ millions)
  • Exhibit 29: Iressa: YoY growth and revenue in emerging markets 2011-2014 ($ millions)
  • Exhibit 30: AstraZeneca: Key takeaways
  • Exhibit 31: Xalkori: Global YoY growth and revenue 2012-2014 ($ millions)
  • Exhibit 32: Pfizer: Key takeaways
  • Exhibit 33: AstraZeneca: Business segmentation by revenue 2014
  • Exhibit 34: AstraZeneca: Business segmentation by revenue 2013 and 2014 ($ billions)
  • Exhibit 35: AstraZeneca: Geographical segmentation by revenue 2014
  • Exhibit 36: Celgene: Product segmentation by revenue 2014
  • Exhibit 37: Celgene: Product segmentation by revenue 2013 and 2014 ($ millions)
  • Exhibit 38: Celgene: Geographical segmentation by revenue 2014
  • Exhibit 39: Eli Lilly: Business segmentation by revenue 2014
  • Exhibit 40: Eli Lilly: Business segmentation by revenue 2013 and 2014 ($ billions)
  • Exhibit 41: Eli Lilly: Geographical segmentation by revenue 2014
  • Exhibit 42: F. Hoffmann-La Roche: Business segmentation by revenue 2014
  • Exhibit 43: F. Hoffmann-La Roche: Business segmentation by revenue 2013 and 2014 ($ billions)
  • Exhibit 44: F. Hoffmann-La Roche: Geographical segmentation by revenue 2014
  • Exhibit 45: Pfizer: Business segmentation by revenue 2014
  • Exhibit 46: Pfizer: Geographical segmentation by revenue 2014
Back to Top